Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel

Circulation Journal

Volumn 75, Issue 1, 2011, Pages 99-105

  Sawada, Takahiro ^a   Shinke, Toshiro ^a   Shite, Junya ^a   Honjo, Tomoyuki ^a   Haraguchi, Yoko ^a   Nishio, Ryo ^a   Shinohara, Masakazu ^a   Toh, Ryuji ^a   Ishida, Tatsuro ^a   Kawamori, Hiroyuki ^a   Kozuki, Amane ^a   Inoue, Takumi ^a   Hariki, Hirotoshi ^a   Hirata, Ken ichi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Clopidogrel; Cyp2c19*2 polymorphism; Drug eluting stent thrombus; Optical coherence tomography

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; PACLITAXEL; RAPAMYCIN;

AGED; ALLELE; ARTICLE; CAUSE OF DEATH; CINEANGIOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY RECANALIZATION; DRUG ELUTING STENT; DRUG RESPONSE; FEMALE; FOLLOW UP; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; HEART INFARCTION; HETEROZYGOTE; HUMAN; JAPANESE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PREDICTION; PROGNOSIS; QUANTITATIVE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STENT THROMBOSIS; THROMBOGENESIS; THROMBOSIS PREVENTION;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR AGENTS; CHI-SQUARE DISTRIBUTION; CINEANGIOGRAPHY; DRUG-ELUTING STENTS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; JAPAN; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PACLITAXEL; PHENOTYPE; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; PROSTHESIS DESIGN; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; THROMBOSIS; TICLOPIDINE; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME;

EID: 78651242921     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0525     Document Type: Article

References (30)

1. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization: Randomized study with the sirolimus-coated Bx velocity balloon expandable stent in the treatment of patients with de novo native coronary lesions. N Engl J Med 2002; 346: 1773-1780.
2. Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ, et al. Stent thrombosis in the modern era: A pooled analysis of multi-center coronary stent trials. Circulation 2001; 103: 1967-1971.
3. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug eluting stents. JAMA 2005; 293: 2126.
4. Macfadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, et al. Late thrombosis in drug eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519-1521.
5. Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 2009; 119: 987-995.
6. King SB, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, et al. 2007 Focused Update of the ACC/AHA/ SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 2008; 117: 261-295.
7. Daemon J, Wenawesar P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-elut-ing and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007; 369: 667-678.
8. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, et al. Impact of platelet reactivity after clopidgrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312-2317.
9. Matezky S, Shenkman B, Guetta V, Shecheter M, Bienart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
10. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis. J Am Coll Cardiol 2005; 46: 1827-1832.
11. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet 2009; 373: 309-317.
12. Schuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical effcacy of clopidogrel therapy. JAMA 2009; 302: 849-858.
13. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, et al. Identifcation of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-207.
14. Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, Dorrler K, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009; 30: 916-922.
15. Mega JL, Close SL, Wiviott SD, Wiviott SD, Shen L, Hockett RD, et al. Cytochrome P450 polymorphism and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
16. Jinnai T, Horiuchi H, Makiyama T, Tazaki J, Tada T, Akao M, et al. Impact of CYP2C19 polymorphism on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan. Circ J 2009; 73: 1498-1503.
17. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, et al. Infuence of omeprazole on the antiplatelet action of clopido-grel association with aspirin. The randomized, double-blind OCLA (Omeprazole CLopidgrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-260.
18. Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB, Loop FD, et al. Guidelines for percutaneous transluminal coronary angio-plasty: A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation 1988; 78: 486-502.
19. Matsumoto D, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D, et al. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: Evaluated by optical coherence tomography. Eur Heart J 2007; 28: 961-967.
20. Sawada T, Shite J, Negi N, Shinke T, Tanino Y, Ogasawara D, et al. Factors that infuence measurements and accurate evaluation of stent apposition by optical coherence tomography: Assessment using a phantom model. Circ J 2009; 73: 1841-1847.
21. Miyoshi N, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D, et al. Comparison by optical coherence tomography of paclitaxel-elut-ing stents with sirolimus-eluting stents implanted in one coronary artery in one procedure: 6-month follow-up. Circ J 2010; 74: 903-908.
22. Otake H, Shite J, Ako J, Shinke T, Tanino Y, Ogasawara D, et al. Local determinant of thrombus formation following sirolimus-elut-ing stent implantation assessed by optical coherence tomography. JACC Cardiovasc Interv 2009; 2: 459-466.
23. Kume T, Akasaka T, Kawamoto T, Ogasawara Y, Watanabe N, Toyota E, et al. Assessment of coronary arterial thrombus by optical coherence tomography. Am J Cardiol 2006; 97: 1713-1717.
24. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahi A, Valina CM, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008; 51: 1925-1934.
25. Nagai H, Ishibashi-Ueda H, Fujii K. Histology of highly echolucent regions in optical coherence tomography images from two patients with sirolimus-eluting stent restenosis. Catheter Cardiovasc Interv 2010; 75: 961-963.
26. Luo HR, Poland RE, Lin KM, Wan YJ. Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: A cross-ethnic comparative study. Clin Pharmacol Ther 2006; 80: 33-40.
27. Takakubo F, Kuwano A, Kondo I. Evidence that poor metabolizers of (5)-mephenytoin could be identifed by haplotypes of CYP2C19 in Japanese. Phamacogenetics 1996; 6: 265-267.
28. Bonello-Palot N, Armero S, Paganelli F, Mancini J, De Labriolle A, Bonello C, et al. Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009; 104: 1511-1515.
29. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Jimenez-Quevedo P, et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 2006; 26: 1895-1900.
30. Huang CC, Chen YC, Leu HB, Chen TJ, Lin SJ, Chan WL, et al. Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention. Am J Cardiol 2010; 105: 1705-1709.